Next |
home / stock / cvm / cvm message board
Subject | By | Source | When |
---|---|---|---|
So are you no longer in either? Just | renaissance1 | investorshub | 04/30/2023 3:07:58 AM |
Sold my 90k in the $2s last may Cheers | sushifishman | investorshub | 04/29/2023 11:04:41 PM |
Hi Hogg | sushifishman | investorshub | 04/29/2023 10:59:03 PM |
for some reason he's way more triggered about | tarius729 | investorshub | 04/29/2023 9:36:04 PM |
Sushi. Are you still in$ NWBO? They seem | renaissance1 | investorshub | 04/29/2023 3:36:22 AM |
Revised Cash Position | sushifishman | investorshub | 04/28/2023 10:52:24 PM |
Doc, I think no one is willing to | G8TSTFL | investorshub | 04/28/2023 2:44:55 PM |
Ahhhh, now you're getting what you aren't getting. | fung_derf | investorshub | 04/28/2023 2:30:44 PM |
Normally, GK would have filed the SEC forms | sushifishman | investorshub | 04/28/2023 2:20:48 PM |
The buyers of the $1.70 see risk | sushifishman | investorshub | 04/28/2023 2:02:03 PM |
The part that I don't get here - | drkazmd65 | investorshub | 04/28/2023 1:17:04 PM |
This aged pretty well Secondary 101: Path to The | sushifishman | investorshub | 04/28/2023 1:54:18 AM |
Offering announced $1.70 | sushifishman | investorshub | 04/28/2023 1:19:06 AM |
84.26% daily short volume on Thursday!! | Phoenix2020 | investorshub | 04/27/2023 11:08:24 PM |
The huge issue with that is in the | exwannabe | investorshub | 04/27/2023 5:08:14 PM |
Will tomorrow bring one dollars? Woof. | sushifishman | investorshub | 04/26/2023 8:18:01 PM |
Woof These zealous Longs wont be happy with that | sushifishman | investorshub | 04/26/2023 11:36:59 AM |
Conditional approval in Canada and Europe for patients | Investors Hub Name | investorshub | 04/26/2023 9:32:13 AM |
Wow! Looks like no one is buying GKs baloney | sushifishman | investorshub | 04/25/2023 2:23:30 PM |
I didnt expect PPS to be in the | sushifishman | investorshub | 04/24/2023 6:27:21 PM |
News, Short Squeeze, Breakout and More Instantly...
Multikine significantly increases overall survival in patients with low levels of tumor cell PD-L1 expression in contrast to approved checkpoint inhibitors 73% survival for Multikine vs 45% in the control arm at 5 years Statistically significant log rank p = 0.0015 ...
Dr. Selvaggi was instrumental in the development and approval of lung cancer drugs Zykadia for Novartis and Opdivo for Bristol Myers Squibb CEL-SCI’s Multikine immunotherapy improves the 5-year survival of head and neck cancer patients to 73% compared to 45% in controls and cut...
CEL-SCI Corporation (NYSE American: CVM) today reported financial results for the quarter ended March 31, 2024, as well as key recent clinical and corporate developments. Clinical and Corporate Developments include: In May 2024, CEL-SCI received the go-ahead from the U.S. Food and D...